Stock LYTIX LYTIX BIOPHARMA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lytix Biopharma

Equities

LYTIX

NO0010405780

Biotechnology & Medical Research

Market Closed - Oslo Bors
Other stock markets
 08:15:00 10/05/2024 pm IST 		5-day change 1st Jan Change
5.48 NOK +0.37% Intraday chart for Lytix Biopharma -6.48% +12.76%
25/04 Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity CI
10/04 Lytix Biopharma to Raise Up to NOK55 Million via Share Offering MT

Valuation

Fiscal Period: December 2023 2024 2025
Capitalization 1 218.8 218.8 -
Enterprise Value (EV) 1 194.7 157 218.8
P/E ratio - - -
Yield - - -
Capitalization / Revenue 48.8 x 34.7 x 16.8 x
EV / Revenue 48.8 x 24.9 x 16.8 x
EV / EBITDA -2.01 x -2.22 x -4.77 x
EV / FCF - - -
FCF Yield - - -
Price to Book - - -
Nbr of stocks (in thousands) 40,068 40,068 -
Reference price 2 5.460 5.460 5.460
Announcement Date 29/02/24 - -
1NOK in Million2
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025
Net sales 1 - 3.991 6.3 13
EBITDA 1 - -96.72 -70.7 -45.9
EBIT 1 - -96.78 -70.7 -45.9
Operating Margin - -2,425.08% -1,122.22% -353.08%
Earnings before Tax (EBT) -56.01 -87.94 - -
Net income -56.01 -87.94 - -
Net margin - -2,203.38% - -
EPS - - - -
Free Cash Flow - - - -
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 16/02/23 29/02/24 - -
1NOK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025
Net Debt 1 - - - -
Net Cash position 1 - 49.6 61.8 -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - - -
ROE (net income / shareholders' equity) - - - -
ROA (Net income/ Total Assets) - - - -
Assets - - - -
Book Value Per Share - - - -
Cash Flow per Share - - - -
Capex - - - -
Capex / Sales - - - -
Announcement Date 16/02/23 29/02/24 - -
1NOK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
LYTIX BIOPHARMA Stock Lytix Biopharma
+12.76% 20.11M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 47.02B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.86B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 41.76B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 28.8B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.05B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.15B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.55B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.34B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.82B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. LYTIX Stock
  4. Financials Lytix Biopharma
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW